user

MHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04™ for Phase 2b Trial in Alzheimer’s Disease

ILAP Designation accelerates patient access and commercialization  MIAMI, APRIL 5, 2023 (GLOBE NEWSWIRE) – ADvantage Therapeutics, Inc. (“ADvantage” or “the...

Brinter Launches Upgraded Pneuma Triaxial Pro “Digital Pneuma Pro“ Bioprinting Head Capable Of Doing Microfluidic Manipulations To Enable More Personalized Tissue Cell Therapy And Transform How Diseases Are Treated

error: Content is protected !!